Suggested remit - To appraise the clinical and cost effectiveness of pentosan polysulfate sodium within its marketing authorisation for treating interstitial cystitis.
Status In progress
Process STA 2018
ID number 1364

Provisional Schedule

Final appraisal document 10 October 2019 - 24 October 2019
Expected publication 13 November 2019

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR)


Companies sponsors Consilient Health (pentosan polysulfate sodium)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Bladder Health UK
  Pelvic Pain Support Network
Professional groups British Association of Urological Surgeons
  Royal College of Physicians


Comparator companies Teva (Cystistat)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
21 August 2019 Committee meeting: 2
11 July 2019 - 01 August 2019 Appraisal consultation
20 June 2019 Committee meeting
22 October 2018 Invitation to participate
22 October 2018 In progress, Invitation to participate
17 May 2018 (14:00) Scoping workshop (London)
23 March 2018 - 24 April 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance